$ICLR

O'Neill Julie sold $150K of ICLR

O'Neill Julie sold 915 shares of ICON PLC (ICLR) at an average of $164.29 ($162.72–$165.51, $0.15M total) across 4 trades on 2026-08-11.

Original reporting
SEC EDGAR · O'Neill Julie
Published Aug 12, 2026, 9:01 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 12, 2026, 9:14 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ICLR
Neutral
medium confidence
Mentioned
$ICLR
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ICLRNeutralLow
01

Why it matters

The disclosure updates insider ownership and confirms an open-market sale of shares at specified prices, but it does not include any new guidance, earnings, or operational developments.

02

Market read

Traders may monitor insider activity for sentiment, but the filing alone is unlikely to drive a sustained repricing without additional company-specific catalysts.

03

What to watch

The article does not state tax, diversification, or personal liquidity context, and it notes no pre-arranged 10b5-1 plan, which can cut both ways for interpretation.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-12, sale executed 2026-08-11

Background

This is an SEC Form 4 insider transaction disclosure for ICON PLC, reported by director O'Neill Julie.

Company-level read

Ticker impact

$ICLRNeutralMedium confidence
Context

ICON PLC director O'Neill Julie sold about 915 shares in open-market trades on 2026-08-11 at $162.72 to $165.51.

Expected impact

Likely limited near-term impact; any effect is more sentiment-driven than fundamental.

Evidence & confidence

The filing discloses transaction details and post-sale holdings, but provides no new company-specific operating, financial, or regulatory information.

Market effects

Minimal; insider Form 4 sales typically do not reset sector expectations.

None indicated.

None indicated.

Counterpoint

Insider sales can be planned for diversification or liquidity needs, so the signal may be overstated versus the absence of any accompanying negative company news.

Key entities

  • ICON PLC

    Subject of the Form 4 insider transaction disclosure.

  • O'Neill Julie

    Director who executed open-market sales totaling about 915 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ICLRMedAI 9/10

ICON plc: ICON Reports Second Quarter 2026 Results

ICON plc (NASDAQ: ICLR) reported Q2 2026 results. Revenue was $2,063.5 million, up 1.4% QoQ. Adjusted EBITDA was $327.2 million (15.9% of revenue). GAAP net income was $72.6 million ($0.94 diluted EPS) and adjusted net income was $198.4 million ($2.56 adjusted EPS). Net business wins were $3,120 million, backlog $23.4 billion, and it reaffirmed 2026 guidance.

$ICLRHighAI 8/10

ICON PLC (ICLR): Financial results for Q2 2026

ICON PLC (ICLR) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 ICON Reports Second Quarter 2026 Results Highlights • Quarter two revenue of $2,063.5 million, an increase of 1.4% on quarter one 2026. • Quarter two adjusted EBITDA of $327.2 million or 15.9% of revenue, an increase of 3.0% on quarter one 2026. • GAAP net income for

$ICLRMed

ICON stock surges 7% on Anthropic AI partnership for trials By Investing.com

ICON plc (NASDAQ:ICLR) shares rose about 7.8% after the company announced a multi-year partnership with Anthropic to integrate Claude AI into its Orbis clinical trial platform. ICON said the collaboration will add four production capabilities, including site intelligence and enrollment risk detection, and will roll out Claude across roles. ICON cited enrollment delays affecting up to 80% of trials.

$ICLRMed

ICON, Anthropic Sign Multi-Year Partnership Deal To Advance AI Capabilities, Stock Up In Pre-Market

ICON Public Limited Company (ICLR) said it signed a multi-year partnership with Anthropic to integrate Claude AI across the clinical trial lifecycle using ICON’s Orbis platform. ICON plans to work with Anthropic’s life sciences team and deploy Claude Code, Claude, and Claude Science. The company cited CEO Barry Balfe. In pre-market, ICLR rose to $177.69, up 5.28% on Nasdaq.